Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 14/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | BCL2 | P10415 | 7/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.47 |
| ▸ | BCL2A1 | Q16548 | 6/20 | 0.42 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354361 | 0.84 | BCL2L1 (0.72) | BCL2L1FFAR1BCL2MCL1BCL2A1 | |
| SCHEMBL19420184 | 0.82 | BCL2L1 (0.69) | BCL2L1FFAR1BCL2MCL1BCL2A1 | |
| SCHEMBL13018809 | 0.72 | BCL2L1 (0.55) | BCL2L1BCL2MCL1BCL2A1 | |
| SCHEMBL13018818 | 0.72 | BCL2L1 (0.55) | BCL2L1BCL2MCL1BCL2A1 | |
| SCHEMBL7887580 | 0.70 | FFAR1 (0.85) | BCL2L1FFAR1FBP1 | |
| SCHEMBL31580496 | 0.69 | FFAR1 (1.00) | BCL2L1FFAR1FBP1 | |
| SCHEMBL14995987 | 0.68 | BCL2L1 (0.51) | BCL2L1BCL2MCL1BCL2A1 | |
| SCHEMBL352947 | 0.68 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL353100 | 0.67 | BCL2L1 (0.60) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL19882790 | 0.66 | BCL2L1 (0.95) | BCL2L1BCL2MCL1BCL2A1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115061-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-08-25 | — | — | US | disclosed |
| US-20090105319-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105319-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | BCL2L1 18/4885FFAR1 2547/4885BCL2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.